MabVax receives orphan drug designation for therapeutic vaccine to treat childhood cancer neuroblastoma
In the U.S., the designation carries significant incentives for the development of drugs to treat rare and difficult diseases. The Company is preparing to commence a Phase 2
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.